News
Precision Medicine May Be Health Care’s Next Big Thing, But We Don’t Yet Know How to Evaluate Precision Drugs
November 9, 2016 /
MATR Sponsor (view all)
Finally, there’s a drug available to treat Duchenne muscular dystrophy, a rare, fatal genetic muscle-wasting disease that grips roughly 10,000 people, mostly boys, in the U.S., who are unlikely to live into their 30s and typically lose the ability to walk in adolescence.
MATR Supporters (view all)
Posted in: Incubators and R&D
Sorry, we couldn't find any posts. Please try a different search.